PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23571810-7	2013	Within subgroup analyses showed significant improvement from placebo in the SG+GG group treated with ABT-925 150 mg. More favorable clinical outcomes were observed in patients treated with ABT-925 150 mg who carried the DRD3 G allele than in those who carried the DRD3 SS genotype.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	101-104	dopamine receptor D3	Homo sapiens	220-224	
23571810-7	2013	Within subgroup analyses showed significant improvement from placebo in the SG+GG group treated with ABT-925 150 mg. More favorable clinical outcomes were observed in patients treated with ABT-925 150 mg who carried the DRD3 G allele than in those who carried the DRD3 SS genotype.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	101-104	dopamine receptor D3	Homo sapiens	264-268	
23571810-7	2013	Within subgroup analyses showed significant improvement from placebo in the SG+GG group treated with ABT-925 150 mg. More favorable clinical outcomes were observed in patients treated with ABT-925 150 mg who carried the DRD3 G allele than in those who carried the DRD3 SS genotype.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	189-192	dopamine receptor D3	Homo sapiens	220-224	
23571810-7	2013	Within subgroup analyses showed significant improvement from placebo in the SG+GG group treated with ABT-925 150 mg. More favorable clinical outcomes were observed in patients treated with ABT-925 150 mg who carried the DRD3 G allele than in those who carried the DRD3 SS genotype.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	189-192	dopamine receptor D3	Homo sapiens	264-268